

May 20, 2022

Ropivacaine Hydrochloride Injection, USP 10 mg/mL Backorder and Allocation Update

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our **Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 20 mL** effective **June 1, 2022 until July 31, 2022**.

During this time, allocations for our **Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 10 mL** will be increased. Contract customers will be allocated **100% of historical 10 mL monthly demand plus 100% of 20 mL demand** on a mL per mL basis in **June**, and **100% of historical 10 mL monthly demand plus 50% of 20 mL demand** on a mL per mL basis in **July**.

Please see the table below for further details.

DIN	Fresenius Kabi Product Code	MDP Product Code	Product Description	Supply Status June 2022	Supply Status July 2022	Supply Status August 2022
02439409	ABA1847	974882	Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 20 mL	Backorder	Backorder	100% Allocation
02439409	ABA1846	974894	Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 10 mL	Allocations increased to cover 100% of 10 mL demand plus 100% of 20 mL demand on mL:mL basis	Allocation reduced to cover 100% of 10 mL demand plus only 50% of 20 mL demand on a mL:mL basis	100% Allocation

We recognize the difficulties and inconvenience that you may encounter as a result of this supply interruption, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,



George Shamsoun
Associate Director – Marketing, IV Drugs
george.shamsoun@fresenius-kabi.com